恶性血液病分子遗传学的发展（英文）.ppt

“ThemoleculargeneticdevelopmentofhematologicmalignancyinJapan”KiyohikoHatake,M.D.,Ph.D.DepartmentofMedicalOncologyandHematology,CancerInstituteHospital,Ariake,Koto,Tokyo,JapanASCO-COSA-CSCO-ESMO-JCOGInternationalSymposiumCSCOAnnualMeeting2008Shanghai,China

DisclosureofCOIResearchfundingChugai/Roche,Kirin,BMS,Kyowa,Yakult,Weyth,Novartis,Pfizer,Taiho,Jansen,Otsuka,BayerEmploymentorleadershipposition:noneStockownershipTakeda,Astellas,Daiichi-Sankyo,DonationPfizer,Kirin,Chugai/Roche,Yakult,Novartis,Jansen,Taiho,Honoraria:noneConsultantoradvisortrole:noneExpertTestimony:none000000000

Today’stalkClinicalpracticeofNHLRegistrationsystemforWHOclassificationofNHLStandardchemotherapyinNHLandHLRCHOPinDLBCLResistancetorituximabLive-cellconfocalfluorescencemicroscopyCDCADCCRelationshipCDCandresponsetorituximabandprognosisMutationofCD20andCDC

ClinicalpracticeofNon-Hodgkin’sLymphoma(B-celllymphoma)inCIHOld,butanimportantprognosticmarkersIL-2R,andCD5inRCHOPtreatment

DLBCL:treatmentresultbyCHOP±RituximabCHOPn=83:76%R-CHOPn=92:97%P=0.00020.05%:3-yearPFSDaysfromtreatmentOver-allsurvivalrate

87casestreatedbyCHOPand141casestreatedbyRCHOPWereanalizedinDLBCL.

RCHOPwassuperiortoCHOPinboth

RCHOPissuperiortoCHOP,andsIL-2RisstillgoodmarkerForprognosis.

MechanismsofactionofrituximabproliferationblockADCCCDCapoptosisNK,Mφ,PMNFcγRC1qC2-C9CD20CD20+lymphomarituximab

ResearchmethodologyPredictionofresponseandprognosisEstablishmentofclinicallyapplicablebio-imagingCancercellsfromthepatientsUltrasuperspeedySensitivitytestLive-cellbio-imagingConfocalfluoresence

PredictionofresponsetorituximabbyimagingResponsetorituximabinlymphomacellsfromthepatientsProbablyineffectiveProbablyeffective10min10min

Theprincipleofimaging-basedCDCsusceptibilityassay

Diagnosticdetailsofpatientsevaluatedf